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Abstract: To report a case of a presumed pyogenic granuloma at the site of multiple intravitreal anti-Vascular Endothelial 
Growth Factor (VEGF) injections. Intravitreal anti-VEGF injections can be complicated by a localized reaction of the 
conjunctiva. 
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INTRODUCTION 
  Age-related macular degeneration (AMD) is one of the 
most common causes of severe, irreversible vision loss in 
older adults in developed countries. Neovascular AMD is 
characterized by abnormal growth of new blood vessels 
under or within the macula [1]. Vascular endothelial growth 
factor A (VEGF) is a key modulator of angiogenesis and 
promotes neovascularization in AMD [1-4]. Currently, 
several anti-VEGF drugs such as pegaptanib, ranibizumab 
and bevacizumab are used via  the intravitreal route for 
treatment of neovascular AMD [5].
 
  Ranibizumab (Lucentis, Genentech, San Francisco, USA) 
is a recombinant humanized monoclonal G1K isotype 
antibody Fab with anti-angiogenetic VEGF A blocking 
properties [1-4]. The Food and Drug Administration (FDA) 
approved Ranibizumab since 2006 as an intravitreal injection 
treatment for neovascular AMD [1,5]. Bevacizumab 
(Avastin, Genentech, San Francisco, USA) is a recombinant 
humanized full-length antibody that binds to all isoforms of 
VEGF. It was initially approved by the FDA for intravenous 
use against metastatic colorectal cancer, but is now 
commonly used off-label to treat a variety of retinal 
disorders including neovascular AMD, diabetic macular 
edema, and retinal vein occlusion [7]. 
  Several adverse reactions after intravitreal injections of 
anti-VEGF treatment have been reported including 
subconjunctival hemorrhage [4-7], conjunctival hyperemia 
[4-7], transient and/or sustained elevated intraocular pressure 
(IOP) [1,4-9],
  anterior uveitis [1,8-10], iatrogenic cataract 
[1,5], vitreous hemorrhage [1,4], retinal tear or detachment 
[1,4], central retinal vein occlusion [4] and endophthalmitis  
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[1,4]. We report a case of a localized, subconjunctival, 
nodular inflammatory reaction at the site of multiple 
ranibizumab injections. Based on clinical appearance, 
anterior segment imaging and improvement with topical 
steroid treatment, we believe this lesion to be a pyogenic 
granuloma. To the best of our knowledge, this is the first 
case of pyogenic granuloma observed following intravitreal 
injections of anti-VEGF therapy. 
CASE REPORT 
  An 87-year-old Caucasian man treated for neovascular 
AMD presented complaining of eye pain and redness one 
week after his last intravitreal ranibizumab injection in the 
right eye (Fig. 1a). The patient received OCT guided 
treatment with bevacizumab (0.125mg/0.05ml) starting in 
October 2005 prior to Federal Drug Administration (FDA) 
approval of ranibizumab for AMD treatment and received 
three bevacizumab (0.125mg/0.05ml) over an 8 month 
period of time. He elected to transition to a treat and extend 
protocol after FDA approval of ranibizumab for treatment of 
neovascular AMD and received twenty-one ranibizumab 
(0.5mg/0.05ml) injections without complications starting 
August 2006 and continued over a 48 month period time 
with his last injection on August 2010. All injections were 
administered 3.5-4mm posterior to the limbus in the 
inferotemporal quadrant varying one or two clock hours 
from previous injection sites using a 32 gauge needle 
following three drops of topical proparacaine (0.5%), two 
drops of ofloxacin (0.3%), and one drop of 5% povidone-
iodine. According to the intravitreal injection protocol 
recommended in the literature, prior to each injection, the 
injection site was dried with a sterile cotton-tipped 
applicator. A wire lid speculum and non-sterile powder-free 
latex gloves were used for all injection procedures [11]. 
  One week post intravitreal injection, the patient had 
stable corrected visual acuity of 20/200 in the affected right 
eye. There was localized, inferotemporal hyperemia of the 60    The Open Ophthalmology Journal, 2011, Volume 5  Jung et al. 
bulbar conjunctiva at the site of the injection. Within the area 
of hyperemia there was an elevated, subconjunctival 
erythematous nodule, which was slightly mobile when 
depressed with a cotton tip applicator (Fig. 1b). There was 
no evidence of perilimbal vessel injection. On eyelid 
eversion, there was no tarsal or forniceal conjunctival 
involvement or foreign body. Anterior exam revealed trace 
cells and 1+ flare reaction in the anterior chamber. No 
hypopyon or vitreous cells were noted. Lens, optic nerve and 
peripheral retinal exam were unremarkable. The left eye was 
unremarkable and showed no evidence of inflammation. 
(1A) 
 
(1B) 
 
Fig. (1). (A) Color photograph shows the appearance of the right 
eye at presentation. There is hyperemia and edema of the 
inferotemporal bulbar conjunctiva. (B) Higher magnification of 
initial erythematous subconjunctival nodule at the site of prior 
intravitreal injection. 
  Slit lamp optical coherence tomography (SL-OCT) (Fig. 
2a) and ultrasound biomicroscopy (UBM) (Fig. 2b) revealed 
a well-circumscribed, solid lesion without scleral 
penetration. The patient was started on ofloxacin (0.3%) and 
rimexolone (1%) four times per day in the right eye. Two 
weeks post-injection, the patient self-discontinued the 
ofloxacin drops and was using only rimexolone twice daily. 
While the nodule persisted and conjunctival hyperemia had 
improved minimally, the patient reported little discomfort. 
He was transitioned to prednisolone acetate (1%) four times 
per day and fluorometholone ointment (0.1%) at bedtime. 
The lesion decreased in size slowly over five months and 
prednisolone acetate was slowly tapered to one drop daily. 
The hyperemia resolved and there was trace 
hyperpigmentation over the area of minimal subconjunctival 
elevation (Fig. 3). Surgical excision and biopsy was deferred 
due to improvement with the topical steroid. The patient’s 
AMD treatment was changed to pro re nata (PRN) optical 
coherence tomography guided dosing and has not since 
required or received any further injections. If clinically 
indicated, another injection site will be considered to prevent 
further complications. 
DISCUSSION 
  Safety profiles are closely monitored in the original 
clinical trials of a medication, but long term use of a 
medication can subsequently lead to the new presentation of 
adverse events or drug reactions [2]. The most common 
ocular adverse events for patients receiving ranibizumab in 
randomized clinical trials were transient subconjunctival 
hemorrhage [4-7], intraocular inflammation [1,8-10] and 
transient and/or sustained elevated intraocular pressure (IOP) 
[1,4-9].
  In one prospective study monitoring for transient 
post injection IOP elevations after ranibizumab injections, 
the authors noted that mild injection site reactions such as 
subconjunctival hemorrhage and /or hyperemia were 
common (59.2%) [6]. 
  Transient ischemia of the ocular surface after intravitreal 
bevacizumab has been reported with nonperfusion of 
conjunctival, episcleral and scleral vessels around the 
injection site. This ischemia, hypothesized to be 
inflammatory in nature, was treated with topical steroids and 
resolved over three weeks [12]. Our case did not show any 
signs of nonperfusion; rather, hyperemia of the blood vessels 
overlying the injection site was seen. 
  Intravitreal ranibizumab injections have rarely been 
associated with noninfectious anterior uveitis [1,8-10]. 
Within one week after injection, our patient developed active 
anterior inflammation and a localized inflammatory reaction 
at the site of intravitreal injection. He had previously 
tolerated multiple bevacizumab and ranibizumab treatments 
without evidence of post-injection inflammation. 
  The differential diagnosis at presentation included 
foreign body reaction, scleral abscess, nodular scleritis, and 
pyogenic granuloma. Anterior imaging with SL-OCT and 
UBM revealed a solid nodule that did not involve the sclera, 
which was consistent with a localized reaction. We believe 
this reaction occurred as a result of inflammatory materials 
deposited in the process of injection, creating a pyogenic 
granuloma reaction and secondary anterior chamber 
inflammation. 
  Pyogenic granulomas are red colored tumors that appear 
on the palpebral or bulbar conjunctiva in areas of 
vascularized tissue submitted to chronic inflammatory injury 
[13-19]. Histopathologically, they contain granulation tissue 
with blood vessels arranged in a fan-shaped configuration 
and have an associated acute and chronic inflammatory cell 
infiltrate in a loose connective tissue stroma [15,16]. 
Although often associated with trauma [14-16], surgery [14-
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granuloma formation after foreign bodies such as natural or 
synthetic fibers [16], contact lens [16], scleral buckle [14], 
and insect wing [14]. We hypothesize that a component of 
the intravitreal injection procedure such as talc from a 
disposable glove, cotton fibers from the sterile applicator, or 
silicone oil derived from the syringe [20-22] could have 
triggered foreign body reaction at the level of the 
conjunctiva. Also, repeated injections in the same quadrant 
of the eye might have increased the risk of this complication. 
 
Fig. (3). Color photograph showing the appearance following 5 
months topical steroid treatment. The conjunctival nodule has 
flattened leaving persistent dilated episcleral vessels and increased 
scleral translucency. 
  Intravitreal anti-VEGF agents including ranibizumab and 
bevacizumab are a safe and effective treatment for 
neovascular AMD [5]. Even with the evidence and safety 
profiles available from the original clinical trials, new 
presentations of adverse events may occur as the usage of 
intravitreal anti-VEGF therapy continues to grow. The safety 
data on these treatment modalities will need to be 
continuously monitored and the potential risks and benefits 
of intravitreal anti-VEGF agents should be discussed with 
patients receiving treatment for neovascular AMD [9]. 
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